Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. company information, Employees & Contact Information

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

Company Details

Employees
446
Founded
-
Address
40 Erie Street, Cambridge,massachusetts 02139,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, Massachusetts
Looking for a particular Intellia Therapeutics, Inc. employee's phone or email?

Intellia Therapeutics, Inc. Questions

News

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Intellia Therapeutics

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - Intellia Therapeutics

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress Intellia Therapeutics

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Therapeutics

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - Intellia Therapeutics

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting Intellia Therapeutics

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - Intellia Therapeutics

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis Intellia Therapeutics

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Therapeutics

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - Intellia Therapeutics

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 Intellia Therapeutics

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases - Intellia Therapeutics

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases Intellia Therapeutics

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein - Intellia Therapeutics

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein Intellia Therapeutics

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) Intellia Therapeutics

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium - Intellia Therapeutics

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast - Intellia Therapeutics

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast Intellia Therapeutics

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform - Intellia Therapeutics

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform Intellia Therapeutics

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Intellia Therapeutics

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine Intellia Therapeutics

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis - Intellia Therapeutics

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Intellia Therapeutics

Intellia Therapeutics to Present at October Healthcare Investor Conferences - Intellia Therapeutics

Intellia Therapeutics to Present at October Healthcare Investor Conferences Intellia Therapeutics

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting - Intellia Therapeutics

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting Intellia Therapeutics

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 - Intellia Therapeutics

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 Intellia Therapeutics

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics - Intellia Therapeutics

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics Intellia Therapeutics

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment - Intellia Therapeutics

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment Intellia Therapeutics

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting - Intellia Therapeutics

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting Intellia Therapeutics

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy Intellia Therapeutics

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 - Intellia Therapeutics

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose - Intellia Therapeutics

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Intellia Therapeutics

Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer - Intellia Therapeutics

Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer Intellia Therapeutics

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 - Intellia Therapeutics

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 Intellia Therapeutics

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones - Intellia Therapeutics

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones Intellia Therapeutics

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia - Intellia Therapeutics

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Intellia Therapeutics

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE) Intellia Therapeutics

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy Intellia Therapeutics

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Intellia Therapeutics

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Intellia Therapeutics

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 20 - Intellia Therapeutics

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 20 Intellia Therapeutics

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency - Intellia Therapeutics

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2020 Financial Results - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2020 Financial Results Intellia Therapeutics

Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy - Intellia Therapeutics

Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy Intellia Therapeutics

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities - Intellia Therapeutics

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities Intellia Therapeutics

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions - Intellia Therapeutics

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions Intellia Therapeutics

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting - Intellia Therapeutics

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Intellia Therapeutics

Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics

Intellia Therapeutics Announces Proposed Public Offering of Common Stock Intellia Therapeutics

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones - Intellia Therapeutics

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones Intellia Therapeutics

Intellia Therapeutics Names Bill Chase to its Board of Directors - Intellia Therapeutics

Intellia Therapeutics Names Bill Chase to its Board of Directors Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia - Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia Intellia Therapeutics

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer - Intellia Therapeutics

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer Intellia Therapeutics

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer - Intellia Therapeutics

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer Intellia Therapeutics

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments - Intellia Therapeutics

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments Intellia Therapeutics

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing - Intellia Therapeutics

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing Intellia Therapeutics

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Intellia Therapeutics

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting Intellia Therapeutics

Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) - Intellia Therapeutics

Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) Intellia Therapeutics

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress - Intellia Therapeutics

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress Intellia Therapeutics

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting - Intellia Therapeutics

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting Intellia Therapeutics

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis - Intellia Therapeutics

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis Intellia Therapeutics

Intellia Corporate Responsibility Report 2024 - Intellia Therapeutics

Intellia Corporate Responsibility Report 2024 Intellia Therapeutics

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference - Intellia Therapeutics

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference Intellia Therapeutics

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis - Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 - Intellia Therapeutics

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 Intellia Therapeutics

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary - Intellia Therapeutics

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary Intellia Therapeutics

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer - Intellia Therapeutics

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer Intellia Therapeutics

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 - Intellia Therapeutics

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 Intellia Therapeutics

Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee - Intellia Therapeutics

Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee Intellia Therapeutics

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy - Intellia Therapeutics

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 - Intellia Therapeutics

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 Intellia Therapeutics

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors - Intellia Therapeutics

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology - Intellia Therapeutics

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology Intellia Therapeutics

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer - Intellia Therapeutics

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer Intellia Therapeutics

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics - Intellia Therapeutics

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics Intellia Therapeutics

Intellia Statement on Germline Editing - Intellia Therapeutics

Intellia Statement on Germline Editing Intellia Therapeutics

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technolog - Intellia Therapeutics

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technolog Intellia Therapeutics

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology - Intellia Therapeutics

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology Intellia Therapeutics

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors - Intellia Therapeutics

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors Intellia Therapeutics

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution - Intellia Therapeutics

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution Intellia Therapeutics

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer - Intellia Therapeutics

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema Intellia Therapeutics

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis - Intellia Therapeutics

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis Intellia Therapeutics

Top Intellia Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant